Abstract
Low-grade chronic inflammation is now being held as an important process in the development of atherosclerosis, with new links between dyslipidemia and inflammation being constantly found. While most studies aim to discover inflammatory pathways leading from dyslipidemia to atherogenesis, there is evidence that inflammation can also act in reverse, altering lipid metabolism in unfavorable ways, possibly creating a vicious cycle of inflammationdyslipidemia- inflammation. This is highly relevant for the search of novel therapeutic targets. In this review, after a brief account of the inflammatory mechanisms leading from dyslipidemia to atherogenesis, we focus on what is currently known about the ways inflammation can impair lipid metabolism and whether anti-inflammatory therapies could have a role in dyslipidemia management.
Keywords: Atherosclerosis, CAD, cholesterol, dyslipidemia, inflammation, lipids.
Medicinal Chemistry
Title:Treating Dyslipidemias: Is Inflammation the Missing Link?
Volume: 10 Issue: 7
Author(s): Nikolaos Papoutsidakis, Spyridon Deftereos, Georgios Giannopoulos, Vasiliki Panagopoulou, Antonis S. Manolis and Georgios Bouras
Affiliation:
Keywords: Atherosclerosis, CAD, cholesterol, dyslipidemia, inflammation, lipids.
Abstract: Low-grade chronic inflammation is now being held as an important process in the development of atherosclerosis, with new links between dyslipidemia and inflammation being constantly found. While most studies aim to discover inflammatory pathways leading from dyslipidemia to atherogenesis, there is evidence that inflammation can also act in reverse, altering lipid metabolism in unfavorable ways, possibly creating a vicious cycle of inflammationdyslipidemia- inflammation. This is highly relevant for the search of novel therapeutic targets. In this review, after a brief account of the inflammatory mechanisms leading from dyslipidemia to atherogenesis, we focus on what is currently known about the ways inflammation can impair lipid metabolism and whether anti-inflammatory therapies could have a role in dyslipidemia management.
Export Options
About this article
Cite this article as:
Papoutsidakis Nikolaos, Deftereos Spyridon, Giannopoulos Georgios, Panagopoulou Vasiliki, Manolis S. Antonis and Bouras Georgios, Treating Dyslipidemias: Is Inflammation the Missing Link?, Medicinal Chemistry 2014; 10 (7) . https://dx.doi.org/10.2174/1573406410666140318101936
DOI https://dx.doi.org/10.2174/1573406410666140318101936 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Experimental and Theoretical Approach to Understand Fever, DENF & its Cure
Infectious Disorders - Drug Targets Mexiletine Metabolites: A Review
Current Medicinal Chemistry Atenolol: Differences in Mode of Action Compared with other Antihypertensives.An Opportunity to Identify Features that Influence Outcome?
Current Pharmaceutical Design When Cells Become a Drug. Endothelial Progenitor Cells for Cardiovascular Therapy: Aims and Reality
Recent Patents on Cardiovascular Drug Discovery COVID-19: A Great Mime or a Trigger Event of Autoimmune Manifestations?
Current Rheumatology Reviews Non-Communicable Diseases and Adherence to Mediterranean Diet
Endocrine, Metabolic & Immune Disorders - Drug Targets New Perspectives of Infections in Cardiovascular Disease
Current Cardiology Reviews Hypertension in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings
Current Vascular Pharmacology Pomegranate Consumption and Blood Pressure: A Review
Current Pharmaceutical Design ATP-Binding Cassette Transporters A1 and G1, HDL Metabolism, Cholesterol Efflux, and Inflammation: Important Targets for the Treatment of Atherosclerosis
Current Drug Targets Cardiovascular Pharmacogenetics of Anti-Thrombotic Agents and Non-Steroidal Anti-Inflammatory Drugs
Current Molecular Medicine Obesity and Cardiovascular Physiology: Impact of some Pharmacological Agents
Current Vascular Pharmacology Endocannabinoid Blockade and the Cardiovascular System
Current Drug Therapy Serum Amyloid A and Its Potential Physiological / Pathological Functions - an Overview of Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Trypanocidal Activity of Nitroaromatic Prodrugs: Current Treatments and Future Perspectives
Current Topics in Medicinal Chemistry Long-Term Outcome of Cardio Respiratory Exercise Performance After Surgery
Current Respiratory Medicine Reviews Recent Advances in Treatment Approaches to Gaucher Disease
Current Pharmaceutical Biotechnology Increased Exercise Favorably Modifies Coronary Artery Disease and Peripheral Arterial Disease Outcomes
Current Vascular Pharmacology Redox Status in Periodontal and Systemic Inflammatory Conditions Including Associated Neoplasias: Antioxidants as Adjunctive Therapy?
Infectious Disorders - Drug Targets